RevBio has received U.S. Food and Drug Administration (FDA) approval to begin a pilot clinical trial of Tetranite, its regenerative bone adhesive.
The adhesive is designed for dental ridge augmentation without membranes, meshes, or fixation devices.
In June 2023, RevBio received a $2 million grant to advance the development of its bone adhesive biomaterial for implant dentistry.




















